Available at research and GMP grade to intensify production of recombinant AAV rAAV viral vectors at any scale from benchtop to 2000L scale bioreactor...
![](https://www.polyplus-sartorius.com/wp-content/uploads/2020/03/FectoVIR-AAV-435x242.png)
Watch this webinar where we address one of the main challenges in bringing AAV-based therapies to patients, is the ability to efficiently translate bench-scale processes to commercial GMP manufacturing while meeting the high dosage requirements. Our Experts from Polyplus, Exothera and Alexion collaborated for the development of a highly scalable AAV manufacturing platform with a capacity ranging from 1L to 200L and 2000L.
Key Learning Objectives: